Entecavir Hydrate

• CAT Number: A001174
• CAS Number: 209216-23-9
• Molecular Formula: C12H15N5O3 • H2O
• Molecular Weight: 295.30
• Purity: ≥95%
• Target: Reverse Transcriptase
• Solubility: >9.7mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one;hydrate
• InChI: InChI=1S/C12H15N5O3.H2O/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20;/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20);1H2/t6-,7-,8-;/m0./s1
• InChIKey: YXPVEXCTPGULBZ-WQYNNSOESA-N
• SMILES: C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2N=C(NC3=O)N.O

Entecavir Hydrate（Cat No.:A001174）is a potent nucleoside analog used in the treatment of chronic hepatitis B virus (HBV) infection. It inhibits HBV DNA polymerase by competing with natural substrates, effectively halting viral replication. Entecavir Hydrate is known for its high selectivity, low resistance rates, and ability to suppress HBV DNA levels, promoting liver health and reducing disease progression. Its excellent oral bioavailability and favorable safety profile make it a preferred choice in HBV management. It is widely used as part of antiviral therapy for long-term disease control.

Reference

1:J Med Virol. 2013 Jun;85(6):987-95. doi: 10.1002/jmv.23564. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.Hagiwara S,Kudo M,Osaki Y,Matsuo H,Inuzuka T,Matsumoto A,Tanaka E,Sakurai T,Ueshima K,Inoue T,Yada N,Nishida N, PMID: 23588724 DOI: 10.1002/jmv.23564 Abstract: The ideal approach to treat chronic hepatitis B remains controversial. This pilot study aimed to evaluate the effectiveness of peginterferon (PEG-IFN) α-2b and entecavir hydrate (ETV) as a combination therapy for patients with chronic hepatitis B, particularly in the context of virological response and the reduction of intrahepatic covalently closed circular DNA (cccDNA). A total of 17 patients with hepatitis B virus (HBV) genotype C were enrolled in this study. All subjects were treated with this combination therapy for 48 weeks and observed for an additional 24 weeks. All patients underwent liver biopsy before and after the therapy period. Changes in cccDNA levels and liver histology were monitored between biopsies. Among the 11 patients who exhibited pre-therapy hepatitis B e antigen (HBeAg), 8 (73%) showed evidence of HBeAg seroconversion by the end of the follow-up period. Serum HBV DNA levels decreased by 5.2 and 3.3 log copies/ml (mean) by the end of the therapy and follow-up periods, respectively. In addition, intrahepatic cccDNA decreased significantly to 1.4 log copies/µg (mean) by the end of the therapy period. Among the 11 patients who did not experience viral relapse, only 2 (18%) exhibited high levels of cccDNA (>4.5 log copies/µg) by the end of the treatment period. In contrast, all relapsed subjects exhibited significantly higher levels of cccDNA than subjects who did not relapse (P  = 0.027). The combination regimen is a promising approach to treat chronic hepatitis B and may achieve significant reduction in serum HBV DNA and intrahepatic cccDNA. Wiley Periodicals, Inc.Copyright © 2013 Wiley Periodicals, Inc.